Related Experiment Video
Updated: Jun 2, 2026
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Emerging drugs for osteoarthritis.
Gloria L Matthews1, David J Hunter
1Genzyme Corporation-Orthopaedics, Framingham, MA 01701, USA. gloria.matthews@genzyme.com
Expert Opinion on Emerging Drugs
|May 6, 2011
Summary
New osteoarthritis (OA) drugs in development aim to modify joint structure and alleviate pain, addressing unmet needs in OA treatment. Further research is crucial for overcoming clinical development challenges.
Area of Science:
- Rheumatology
- Pharmacology
- Biomedical Engineering
Background:
- Osteoarthritis (OA) is a widespread joint disease affecting 13% of the global population and is the primary cause of disability in US adults over 65.
- Characterized by cartilage loss, bone remodeling, and inflammation, OA leads to joint pain and functional impairment.
- Current OA treatments primarily manage symptoms, with over 75% of patients needing additional relief and no disease-modifying therapies available.
Purpose of the Study:
- To review drugs in Phase II-III clinical trials for osteoarthritis (OA) pain and structural degeneration.
- To identify emerging therapeutic targets and assess their potential for disease modification.
Main Methods:
- Literature review of drugs in late-stage development (Phase II-III) for OA.
- Focus on pharmacological interventions targeting OA pain and structural changes.
- Exclusion of procedural, behavioral, and device-based treatments.
Main Results:
- Several drug candidates are in late-stage development for OA, targeting pain and structural degeneration.
- These novel therapeutics represent potential advancements beyond current symptomatic treatments.
- The review highlights the pipeline of OA drug development.
Conclusions:
- A deeper understanding of OA pathophysiology and the connection between symptoms and structural changes is key to developing novel therapies.
- Significant challenges remain in clinical development, including disease progression patterns and outcome measure standardization for pain and structural modification.
- Future research and improved clinical trial designs are essential for bringing effective OA treatments to patients.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications